Form 4: Madrigal Pharmaceuticals Director Sells Shares

Director Richard S. Levy sold 5,282 shares of Madrigal Pharmaceuticals common stock via a Rule 10b5-1 trading plan.

Summary

• Director Richard S. Levy executed a series of stock sales on May 22, 2026.
• A total of 5,282 shares were sold at weighted average prices ranging from $506.675 to $519.98 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2026.
• Following these transactions, the director retains 22,015 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were executed under a pre-established 10b5-1 plan, which is a standard administrative procedure for insiders.

Positives

• The sales were pre-planned under a Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the director's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on current valuation.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is common in the biotechnology sector, often used by executives for liquidity or portfolio diversification rather than reflecting a change in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected as the sales were pre-planned and represent a small portion of the director's total holdings.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, Insider Trading, Form 4, Biotech, Director Sale